Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $68.7500 on Bristol-Myers Squibb Company (NYSE:BMY) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $2.6300 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Bristol-Myers Squibb Company (NYSE:BMY) stands at 34.9547.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Bristol-Myers Squibb Company Co, the PEG ratio for coming 3-5 years is 1.1600.
The technical analysis highlights that Bristol-Myers Squibb Company Co current is trading $-10.1272 points away or -14.4882% from its 50-day moving average of $69.8997. Further it is trading $-8.7039 or -12.7108% away its 200-day moving average of $68.4764.
The 52-week high of Bristol-Myers Squibb Company (NYSE:BMY) was $77.1200 while lowest point recorded in 52-week was $56.3200. It implies if stock price makes a movement of over $-17.3475, it will record a new 52-week high. In the case of +6.1301% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...